Corbus to Present Phase 1/2 CRB-701 Durability Data at ASCO, Plans HNSCC Trial
Corbus Pharmaceuticals will present updated Phase 1/2 CRB-701 data at the 2026 ASCO meeting, highlighting response durability and head and neck cancer subgroup analysis. The company plans to start a registrational second-line HNSCC trial mid-2026 and report CRB-701 plus Keytruda combination results in first-line HNSCC in Q4 2026.
1. ASCO 2026 Abstract Presentations
Corbus will present updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, at the 2026 ASCO Annual Meeting. Sessions include an oral presentation on cervical cancer (May 29, 4:57 PM CDT, Abstract #5508) and a poster on head and neck cancer (May 30, 4:30 PM CDT, Abstract #6062, Board 519), covering response durability and subgroup analysis.
2. Registrational Second-Line HNSCC Trial
The company expects to initiate a registrational Phase 2 trial of CRB-701 in second-line head and neck squamous cell carcinoma by mid-2026, aiming to build on Phase 1/2 efficacy and safety findings and support potential future approvals.
3. Keytruda Combination Data Outlook
Corbus anticipates reporting CRB-701 combined with Keytruda results in first-line HNSCC patients in Q4 2026, a milestone intended to inform additional registration-enabling studies and expand the ADC’s clinical utility.